Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Intra-patient Crossover, Safety, Biomarker and Anti-Tumor Activity Assessment of the Combination of Atezolizumab and Vigil in Patients With Advanced Gynecological Cancers (A Companion Study to CL-PTL-119)

NCT03073525 is registered in ClinicalTrials.gov with Gradalis, Inc. as lead sponsor.

NCT NCT03073525
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03073525 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Intra-patient Crossover, Safety, Biomarker and Anti-Tumor Activity Assessment of the Combination of Atezolizumab and Vigil in Patients With Advanced Gynecological Cancers (A Companion Study to CL-PTL-119)
Lead sponsor
Gradalis, Inc.
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2017
Completion date
May 18, 2022
Enrollment
25 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

advanced gynecological cancers, cervical cancer, ovarian cancer, uterine cancer